Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded up $0.75 during midday trading on Friday, hitting $40.25. The company had a trading volume of 715,964 shares, compared to its average volume of 843,788. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. Pacira Pharmaceuticals’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $0.20 EPS. equities analysts expect that Pacira Pharmaceuticals, Inc. will post -0.87 earnings per share for the current year.

WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) CEO Sells $2,257,650.90 in Stock” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/17/pacira-pharmaceuticals-inc-pcrx-ceo-sells-2257650-90-in-stock.html.

Several brokerages have commented on PCRX. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. Jefferies Group LLC dropped their price target on Pacira Pharmaceuticals to $52.00 and set a “buy” rating for the company in a research report on Thursday, November 9th. HC Wainwright reiterated a “buy” rating and set a $52.00 price target on shares of Pacira Pharmaceuticals in a research report on Thursday, November 9th. Finally, Canaccord Genuity lifted their price target on Pacira Pharmaceuticals from $33.00 to $38.00 and gave the company a “hold” rating in a research report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $49.71.

Several hedge funds and other institutional investors have recently made changes to their positions in PCRX. BlackRock Inc. raised its holdings in shares of Pacira Pharmaceuticals by 28,922.7% during the 1st quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after buying an additional 3,172,817 shares in the last quarter. HealthCor Management L.P. increased its stake in Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after purchasing an additional 693,799 shares during the period. Eaton Vance Management purchased a new position in Pacira Pharmaceuticals in the 2nd quarter worth approximately $19,519,000. Mesirow Financial Investment Management Equity Management purchased a new position in Pacira Pharmaceuticals in the 3rd quarter worth approximately $14,671,000. Finally, Stonepine Capital Management LLC purchased a new position in Pacira Pharmaceuticals in the 3rd quarter worth approximately $14,089,000. 99.64% of the stock is currently owned by institutional investors.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.